TITLE: Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a 3D human liver-immunocompetent co-culture system

Authors Affiliation: Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA: US, KCR, CLY, DRB, JY, MC, JSW, DAL, LGG, SRT. Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA: SRT. CN Bio Innovations Ltd, Biopark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK: EL, DJH. This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 27, 2017 as DOI: 10.1124/dmd.116.074005

[1]  David J Hughes,et al.  Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease , 2017, World journal of gastroenterology.

[2]  L. Griffith,et al.  Modeling Therapeutic Antibody–Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform , 2016, Drug Metabolism and Disposition.

[3]  S. Strom,et al.  Addition of Dexamethasone Alters the Bile Acid Composition by Inducing CYP8B1 in Primary Cultures of Human Hepatocytes. , 2016, Journal of clinical and experimental hepatology.

[4]  Frank Jacobs,et al.  In Vitro Model for Hepatotoxicity Studies Based on Primary Human Hepatocyte Cultivation in a Perfused 3D Bioreactor System , 2016, International journal of molecular sciences.

[5]  Hong Liang,et al.  Structural Basis of Non‐Steroidal Anti‐Inflammatory Drug Diclofenac Binding to Human Serum Albumin , 2015, Chemical biology & drug design.

[6]  Georg Damm,et al.  Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI , 2015, Mediators of inflammation.

[7]  W. Wong,et al.  Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. , 2015, Chemical research in toxicology.

[8]  G. Szabo,et al.  Inflammasome activation and function in liver disease , 2015, Nature Reviews Gastroenterology &Hepatology.

[9]  L. Griffith,et al.  Metabolite Profiling and Pharmacokinetic Evaluation of Hydrocortisone in a Perfused Three-Dimensional Human Liver Bioreactor , 2015, Drug Metabolism and Disposition.

[10]  Chitra Kanchagar,et al.  Establishment of a Hepatocyte-Kupffer Cell Coculture Model for Assessment of Proinflammatory Cytokine Effects on Metabolizing Enzymes and Drug Transporters , 2015, Drug Metabolism and Disposition.

[11]  L. Griffith,et al.  Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system , 2014, British Journal of Cancer.

[12]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[13]  J. Kelm,et al.  Multi-cell type human liver microtissues for hepatotoxicity testing , 2012, Archives of Toxicology.

[14]  K. Kodys,et al.  IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. , 2012, The Journal of clinical investigation.

[15]  Melvin E. Andersen,et al.  Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.

[16]  P. Mandrekar,et al.  An essential role for monocyte chemoattractant protein‐1 in alcoholic liver injury: Regulation of proinflammatory cytokines and hepatic steatosis in mice , 2011, Hepatology.

[17]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[18]  Wajahat Mehal1,et al.  Cell Death and Fibrogenesis , 2010, Seminars in liver disease.

[19]  Walker Inman,et al.  Liver tissue engineering in the evaluation of drug safety , 2009, Expert opinion on drug metabolism & toxicology.

[20]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[21]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[22]  Albert P. Li,et al.  Human hepatocytes: isolation, cryopreservation and applications in drug development. , 2007, Chemico-biological interactions.

[23]  J Brian Houston,et al.  Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.

[24]  Ivan Rusyn,et al.  Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  K. Sen,et al.  Binding of diclofenac sodium with bovine serum albumin at different temperatures, pH and ionic strengths. , 2006, Indian journal of experimental biology.

[26]  M. T. Donato,et al.  Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. , 2004, Current drug metabolism.

[27]  U. Boelsterli,et al.  Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. , 2003, Toxicology and applied pharmacology.

[28]  Wei Tang.  The metabolism of diclofenac--enzymology and toxicology perspectives. , 2003, Current drug metabolism.

[29]  Silvio Albertini,et al.  Modulation of gene and protein expression by carbon tetrachloride in the rat liver. , 2002, Toxicology and applied pharmacology.

[30]  H. Blum.  Molecular Targets for Prevention of Hepatocellular Carcinoma , 2002, Digestive Diseases.

[31]  D. Russell,et al.  Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. , 2001, Journal of lipid research.

[32]  I. Björkhem,et al.  Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid , 2000, Hepatology.

[33]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[34]  A Boobis,et al.  Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. , 1999, Biochemical pharmacology.

[35]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[36]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[37]  C. Dinarello,et al.  Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. , 1992, Blood.

[38]  V. A. Skoutakis,et al.  Review of Diclofenac and Evaluation of its Place in Therapy as a Nonsteroidal Antiinflammatory Agent , 1988, Drug intelligence & clinical pharmacy.

[39]  R. N. Brogden,et al.  Diclofenac Sodium: A Review of its Pharmacological Properties and Therapeutic Use in Rheumatic Diseases and Pain of Varying Origin , 1980, Drugs.

[40]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.